Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Agitation Associated With: later-stage trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Agitation Associated With: 2 US clinical trials tracked, none currently recruiting.
Agitation Associated With is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Otsuka Pharmaceutical Development & Commercialization, running 2 of these trials.
Enrollment posture brief
Registry condition agitation-associated-with
OPEN 0 | RECR 0% | LATE 2 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Agitation Associated With has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Agitation Associated With on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Agitation Associated With is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Otsuka Pharmaceutical Development & Commercialization
NCT01862640
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization
NCT01922258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Agitation Associated With records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Agitation Associated With trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Agitation Associated With page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Agitation Associated With trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Otsuka Pharmaceutical Development & Commercialization sponsors the most Agitation Associated With trials on record, review their full trial history before evaluating a specific study. See Otsuka Pharmaceutical Development & Commercialization's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Agitation Associated With condition card totals 2 registered trials; most-linked intervention Brexpiprazole, OPC-34712; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.